AU2001246516B2 - Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract - Google Patents

Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract Download PDF

Info

Publication number
AU2001246516B2
AU2001246516B2 AU2001246516A AU2001246516A AU2001246516B2 AU 2001246516 B2 AU2001246516 B2 AU 2001246516B2 AU 2001246516 A AU2001246516 A AU 2001246516A AU 2001246516 A AU2001246516 A AU 2001246516A AU 2001246516 B2 AU2001246516 B2 AU 2001246516B2
Authority
AU
Australia
Prior art keywords
cdr2
cdr3
tyr
amino acid
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001246516A
Other languages
English (en)
Other versions
AU2001246516A1 (en
Inventor
Hansjoerg Adam
Lothar Farber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001246516A1 publication Critical patent/AU2001246516A1/en
Application granted granted Critical
Publication of AU2001246516B2 publication Critical patent/AU2001246516B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001246516A 2000-03-30 2001-03-28 Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract Ceased AU2001246516B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0007911.1 2000-03-30
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Publications (2)

Publication Number Publication Date
AU2001246516A1 AU2001246516A1 (en) 2001-12-20
AU2001246516B2 true AU2001246516B2 (en) 2005-06-30

Family

ID=9888901

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001246516A Ceased AU2001246516B2 (en) 2000-03-30 2001-03-28 Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
AU4651601A Pending AU4651601A (en) 2000-03-30 2001-03-28 Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU4651601A Pending AU4651601A (en) 2000-03-30 2001-03-28 Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Country Status (18)

Country Link
US (2) US20050226872A1 (cg-RX-API-DMAC7.html)
EP (1) EP1268553A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528890A (cg-RX-API-DMAC7.html)
KR (2) KR20020084107A (cg-RX-API-DMAC7.html)
CN (1) CN1416432A (cg-RX-API-DMAC7.html)
AU (2) AU2001246516B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109549A (cg-RX-API-DMAC7.html)
CA (1) CA2401249A1 (cg-RX-API-DMAC7.html)
GB (1) GB0007911D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0301846A3 (cg-RX-API-DMAC7.html)
IL (1) IL151089A0 (cg-RX-API-DMAC7.html)
NO (1) NO20024579L (cg-RX-API-DMAC7.html)
NZ (1) NZ520547A (cg-RX-API-DMAC7.html)
PL (1) PL357014A1 (cg-RX-API-DMAC7.html)
RU (1) RU2286797C2 (cg-RX-API-DMAC7.html)
SK (1) SK13892002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001072845A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207736B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006604A2 (en) * 1998-07-27 2000-02-10 Novartis Ag Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006604A2 (en) * 1998-07-27 2000-02-10 Novartis Ag Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kovarik J. et al., Clinical Pharmacology and Therapeutics, 1998, 64(1), 66-72 *

Also Published As

Publication number Publication date
RU2286797C2 (ru) 2006-11-10
NO20024579D0 (no) 2002-09-24
IL151089A0 (en) 2003-04-10
PL357014A1 (en) 2004-07-12
CA2401249A1 (en) 2001-10-04
NZ520547A (en) 2005-04-29
RU2002127800A (ru) 2004-03-27
WO2001072845A1 (en) 2001-10-04
US20050226872A1 (en) 2005-10-13
SK13892002A3 (sk) 2003-05-02
HUP0301846A3 (en) 2010-07-28
CN1416432A (zh) 2003-05-07
KR20080079702A (ko) 2008-09-01
ZA200207736B (en) 2003-05-08
EP1268553A1 (en) 2003-01-02
KR20020084107A (ko) 2002-11-04
GB0007911D0 (en) 2000-05-17
JP2003528890A (ja) 2003-09-30
NO20024579L (no) 2002-11-11
US20090041775A1 (en) 2009-02-12
HUP0301846A2 (hu) 2003-09-29
BR0109549A (pt) 2003-06-10
AU4651601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
US20090041775A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP5905534B2 (ja) 多発性硬化症を治療する方法
AU2001246516A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
US20230043949A1 (en) Methods for the treatment of chronic pouchitis
WO2017165125A1 (en) Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
JP2003528890A5 (cg-RX-API-DMAC7.html)
CN117298268A (zh) 治疗或预防移植物抗宿主疾病的方法
US20240182581A1 (en) Methods for the treatment of chronic pouchitis
CN122028914A (zh) 自身免疫性疾患的联合治疗
AU2002315271B2 (en) Use of CD25 binding molecules in steroid-resistant patients
EP1100829B1 (en) Use of basiliximab in the treatment of rheumatoid arthritis or skin diseases
RU2318537C2 (ru) Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
TW202613167A (zh) 使用抗ｔｌ１ａ抗體治療發炎性腸病之方法
Dispenzieri POEMS syndrome and other atypical plasma cell disorders
Albenberg et al. Biologics for the treatment of moderate-to-severe ulcerative colitis in pediatric patients

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired